SPOTLIGHT: Cardiome delays analysis


There's plenty of buzz this morning about Cardiome Pharma, which announced that it is delaying an interim analysis on a key heart drug--vernakalant--so it can add data from more patients in the Phase IIb study. Analysts say the company is likely involved in partnership talks. Cardiome now expects to release the analysis in March. Release

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.